Evidence map›Paper›PMID 33923006›Full record

ArticleMolecules (Basel, Switzerland)2021

Predicting Absorption-Distribution Properties of Neuroprotective Phosphine-Borane Compounds Using In Silico Modeling and Machine Learning.

Raheem Remtulla, Sanjoy Kumar Das, Leonard A Levin

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Design, Synthesis, and Evaluation ofMolecules (Basel, Switzerland) · 2024
    Article
  4. Physicochemical characterization ofRSC medicinal chemistry · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Raheem RemtullaDepartment of Ophthalmology and Visual Sciences, McGill University, Montreal, QC H4H 3S5, Canada.
Sanjoy Kumar DasDrug Discovery Core, Research Institute, McGill University Health Centre, Montreal, QC H4A 3J1, Canada.
Leonard A LevinDepartment of Ophthalmology and Visual Sciences, McGill University, Montreal, QC H4H 3S5, Canada.

Funding

Development of redox-active therapies for ischemic optic neuropathyR21EY025074 · NEI · UNIVERSITY OF WISCONSIN-MADISON · PI LEVIN, LEONARD A · 2015 to 2016
$421k
CIHR PJT-162396NIH HHS R21EY025074
6 · The paper itself

Abstract

Phosphine-borane complexes are novel chemical entities with preclinical efficacy in neuronal and ophthalmic disease models. In vitro and in vivo studies showed that the metabolites of these compounds are capable of cleaving disulfide bonds implicated in the downstream effects of axonal injury. A difficulty in using standard in silico methods for studying these drugs is that most computational tools are not designed for borane-containing compounds. Using in silico and machine learning methodologies, the absorption-distribution properties of these unique compounds were assessed. Features examined with in silico methods included cellular permeability, octanol-water partition coefficient, blood-brain barrier permeability, oral absorption and serum protein binding. The resultant neural networks demonstrated an appropriate level of accuracy and were comparable to existing in silico methodologies. Specifically, they were able to reliably predict pharmacokinetic features of known boron-containing compounds. These methods predicted that phosphine-borane compounds and their metabolites meet the necessary pharmacokinetic features for orally active drug candidates. This study showed that the combination of standard in silico predictive and machine learning models with neural networks is effective in predicting pharmacokinetic features of novel boron-containing compounds as neuroprotective drugs.

Indexed as

Machine LearningBlood-Brain BarrierBoranesComputer SimulationHumansNeuroprotectionNeuroprotective AgentsPhosphinesProtein BindingBoranesNeuroprotective AgentsphosphinePhosphinesneural networksneuroprotectionpharmacokineticsphosphine-borane compounds

Identifiers

PMID33923006
PMCPMC8123347

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.